INJEX Pharma AG
INJEX Pharma AG: INJEX share prospectus approved by the German Federal Financial Supervisory Authority (BaFin)
INJEX Pharma AG / Key word(s): Miscellaneous Corporate News: INJEX share prospectus approved by the German Federal Financial Supervisory Authority (BaFin) Berlin, February 27, 2013 – INJEX Pharma AG is pleased to announce that the German Federal Financial Supervisory Authority (BaFin) approved yesterday the share prospectus of the company. The prospectus is from now on available on the Company’s website at www.injex.com. INJEX Pharma aims to achieve a listing on the regulated market of the Frankfurt Stock Exchange (segment General Standard) – an approved prospectus by BaFin is a precondition. A stock exchange listing on the regulated market is delivering increased visibility on the capital markets for the company and is part of the implementation of the growth strategy. The desired listing in General Standard will broaden the shareholder base of the company even more and will make it easier to trade the shares for international investors. The admission of shares is expected on March 11, 2013 in the regulated market of the Frankfurt Stock Exchange in the General Standard segment. The listing is expected on March 18, 2013. A change of this timetable is still possible. The securities code number of the shares is ISIN: DE000A0STYL7, the WKN number is WKN: A0STYL. For further information on INJEX Pharma AG and its subsidiaries, please refer to www.injex.com. For further questions please contact our Investor Relations team directly: INJEX Pharma AG t: +49 89 24 41 18 – 223 INJEX Pharma AG: End of Corporate News 27.02.2013 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
202460 27.02.2013 |